Eculizumab in Primary MPGN
This trial is active, not recruiting.
|Sponsor||Mario Negri Institute for Pharmacological Research|
|Collaborator||Alexion Pharma Italy s.r.l.|
|Start date||March 2014|
|End date||March 2017|
|Trial size||10 participants|
|Trial identifier||NCT02093533, 2013-003826-10, EAGLE|
Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative complement pathway and familial forms for all types of MPGN have been reported suggesting that genetic abnormalities may play a predisposing role to the disease. In recent case reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex ,is a safe and effective therapy.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Bari, Italy||Ospedale Pediatrico "Giovanni XXIII" - U:O Nefrologia||no longer recruiting|
|Bergamo, Italy||A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò||no longer recruiting|
|Bologna, Italy||Policlinico Sant'Orsola -Malpighi - U.O.S. Nefrologia e dialisi pediatrica||no longer recruiting|
|Messina, Italy||Policlinico "G.Martino" - U.O. Nefrologia e Dialisi||no longer recruiting|
|Padova, Italy||Policlinico Universitario di Padova - U.O. Nefrologia Pediatrica||no longer recruiting|
|Bolzano, Italy||Ospedale Centrale||no longer recruiting|
|Napoli, Italy||Policlinico "Federico II" - U.O. Nefrologia||no longer recruiting|
|Rimini, Italy||Ospedale degli Infermi - U.O. Nefrologia e Dialisi||no longer recruiting|
|Roma, Italy||C.I. Columbus-Università Cattolica del S.Cuore - UOC Nefrologia e Dialisi||no longer recruiting|
|Roma, Italy||Ospedale Pediatrico "Bambin Gesù" - U.O. Nefrologia||no longer recruiting|
|Torino, Italy||Presidio Ospedaliero O.I.R.M. "Sant'Anna" - U.O. Nefrologia||no longer recruiting|
|Trento, Italy||Ospedale "Santa Chiara" - U.O. Nefrologia||no longer recruiting|
|Treviso, Italy||Ospedale Cà Foncello - U.O. Nefrologia||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
time frame: Changes from baseline at week 1,12,24,36,48 and 72.
Terminal complement complex (sC5b-9) levels
time frame: Changes from baseline at 1,2, 3, 4,12,24,36,48,52,56,60 and 72 week.
Glomerular filtration rate (GFR) measured by iohexol plasma clearance and estimated.
time frame: Changes from Baseline at 1,24, 48 and 72 week.
Time to disease progression.
time frame: Up 72 week.
Male or female participants up to 75 years old.
Inclusion Criteria: - Biopsy-proven primary MPGN - Creatinine clearance >20 ml/min per 1.73m2 - 24-hour proteinuria persistently exceeding 3,5g in adults or exceeding 40mg/h/m2 in children (or exceeding 2mg protein/mg creatinine in children spot urine samples) - Persistently low C3 levels in at least two consecutive evaluations - Persistently high sC5b9 levels (>1000 ng/ml) in at least two previous consecutive evaluations - Written informed consent (by parents or tutors if underage) Exclusion Criteria: - Age ≥75 years - Secondary MPGN (evidence of infection, immunological disease including vasculitis, systemic diseases and proliferative disorders) - Evidence at kidney biopsy evaluation of severe chronic histological changes that very unlikely could benefit of eculizumab therapy - Concomitant steroid or immunosuppressive therapy for immuno-mediated disease - Pregnancy or lactating - Childbearing potential without effective contraception - Any clinically relevant condition that might affect completion of the study participation and/or confound study results - Inability to understand the potential risks and benefits of the study - Legal incapacity
|Official title||EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA|
Call for more information